A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 873
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : GVL
Long Form : graft-versus-leukemia
No. Year Title Co-occurring Abbreviation
2021 A novel clinically relevant graft-versus-leukemia model in humanized mice. allo-SCT, AML, HSCs
2021 Chimerism, the Microenvironment and Control of Leukemia. GVH, GVHD
2021 Drug delivery formulation impacts cyclosporine efficacy in a humanised mouse model of acute graft versus host disease. aGVHD, CyA
2021 Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. haplo-SCT, MHC, MSDT
2021 Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect. allo-HCT, GMP, GVHD, HuMoSC
2021 Graft Versus Leukemia: Current Status and Future Perspectives. ---
2021 Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study. ALL, AML, CI, CRS, GVHD, HSCT, MMF, PTB
2021 IL-17-producing γδT cells ameliorate intestinal acute graft-versus-host disease by recruitment of Gr-1+CD11b+ myeloid-derived suppressor cells. aGVHD, IL, MDSCs
2021 Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation. GVHD
10  2021 Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. ICB
11  2021 Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. HSCT, R/R
12  2021 Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax. allo-HSCT, CLL, ECP, GVHD, HLA, IP, IS, LDH, MMF, PTLD
13  2021 Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT. allo-HSCT, GVHD
14  2021 The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation. allo-HCT
15  2021 Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. allo-HCT, GM-CSF, GVHD, IL-2, PD-L1, TAC, Tr1
16  2020 ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome. GVHD
17  2020 Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. BEN-TBI, BMT, CY, GVHD, HCT
18  2020 Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease. BMT, DCs, GVHD
19  2020 Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance. APCs, FasL, GVHD, HSCT, MPBC
20  2020 Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. AML, GVHD, HCT, MDS
21  2020 Decline of serum albumin precedes severe acute GvHD after haploidentical HSCT. GVHD, HSCT
22  2020 Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. CIR, haplo-SCT, LFS, MSDT, NRM, OS, Ph, pre-MRD
23  2020 Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. GVHD, HCT, MAP, NRM
24  2020 Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. allo-HSCT, CLL, HLA
25  2020 Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation. allo-HSCT, GVHD
26  2020 Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. AML, FLT3-ITD, FLT3-TKI
27  2020 Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells. DCs, DEC, DLI, GVHD
28  2020 Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. allo-HCT, GLP-2, GVHD, ISCs, PCs
29  2020 Glucocorticoids delivered by inorganic-organic hybrid nanoparticles mitigate acute graft-versus-host disease and sustain graft-versus-leukemia activity. aGVHD, GCs, GR, IOH-NPs
30  2020 Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumors allo-HSCT, GVT, RDICs, TIL
31  2020 H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect. allo-HSCT, GVHD, HRA, MHC, MiHAs
32  2020 HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. allo-SCT, GVHD, MiHA
33  2020 Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. ADCs, allo-SCT, AML, DLI, GVHD, mAbs, NK
34  2020 Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. allo-HCT, AML, CAR, DCs, GVHD
35  2020 Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. allo-SCT, AML, HMA
36  2020 Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. CI, GVHD, HR, HSCT, MRD, Ph-positive ALL
37  2020 Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. GVHD, HLA, HSCT, KIRs, NK
38  2020 Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease. allo-HCT, GVHD
39  2020 Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. GVHD, HCT
40  2020 Minor Histocompatibility Antigen-Specific T Cells. GVHD, HCT, HLA, MHC
41  2020 Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. allo-HSCT, AML, FDA
42  2020 Phenotypic and Functional Characterization of NK Cells in alphabetaT-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. haplo-HSCT, HCMV, HSCs
43  2020 Priming of Allo-HLA-DP-Specific Reactivity from the Naïve T Cell Compartment Is Not Exclusively Mediated by Professional Antigen-Presenting Cells. allo, APCs, GVHD
44  2020 Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis. ATG-F, DLI, HR, HSCT, LFS, OS, pro-DLI
45  2020 T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. ---
46  2020 T cell optimization for graft-versus-leukemia responses. HCT, TCRs
47  2020 T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies. CAR, TAA
48  2020 Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia. allo-HSCT, GVHD, HDACs
49  2020 Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. B-ALL, GVHD, ITK, ITK
50  2020 Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. allo-HCT, AP, CP, DC, LP
51  2020 Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation. aGVHD, GVHD, MDSCs, MSCs, PBMCs, UCB-MSCs
52  2020 Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. AML, BM, CIRs, HID-HSCT, LFS, NRM, OS, PIF, R/R
53  2020 [Animal models in the study of allogeneic hematopoietic stem cell transplantation]. GVHD, SCT
54  2019 Biomarkers in acute graft-versus-host disease: new insights. FDA, GI, GVHD, HCT, MAGIC, MAP, NIH, NRM
55  2019 Caspase-11 signaling enhances graft-versus-host disease. allo-HSCT, GSDMD, GVHD, IL-1alpha
56  2019 Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. allo-HCT, CPB, GVHD
57  2019 Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). allo-HSCT, AML, CAR
58  2019 Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. H-AML, HID, MSD
59  2019 Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. allo-SCT, AML, CAR, CTLs, DLI, GVHD, MRD, TCR
60  2019 Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. AML, MRD, SCT
61  2019 Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. allo-HSCT, AML
62  2019 Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. BO, GVHD
63  2019 Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner. allo-HCT, GVHD, iNKT
64  2019 Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft? haplo-SCT, MSDT
65  2019 Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease. APC, CTL, GVHD, HSC
66  2019 NK Cell Reconstitution in Paediatric Leukemic Patients after T-Cell-Depleted HLA-Haploidentical Haematopoietic Stem Cell Transplantation Followed by the Reinfusion of iCasp9-Modified Donor T Cells. BM, HD, HLA, HSCT, NK, PB, TCD
67  2019 Pegylated interferon-2alpha invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation. DLI, GVHD, OS, PEG-IFN-alpha, PFS, SCT
68  2019 Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia. allo-HSCT, GVHD, HR, iNKT, M-MDSCs
69  2019 Rapid review: next generation of cord blood banks; transplantation and beyond. CB, GVH, RBC
70  2019 Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. allo-HSCT, CML, HLAs, KIRs, NK
71  2019 Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. GVHD, HCT
72  2019 Safety and efficacy of fresh whole blood donor lymphocyte infusion in children. DLI, HSCT
73  2019 Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. allo-SCT, GVHD, HLA, NK
74  2019 The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance. aGVHD
75  2019 The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models. aGVHD, CCR7, HSCT
76  2019 The Graft-Versus-Leukemia Effect in AML. allo-SCT, AML, GVHD
77  2019 The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. aGVHD, ALL, cGVHD, GVHD, HR, OS
78  2019 The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells. allo-HSCT, GVHD, MDSCs
79  2019 The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease. allo-HCT, GVHD, MHC, TCD, TCR
80  2019 Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease. allo-BMT, allo-HCT, GVHD, ROS, Trx1
81  2019 Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse. allo-HCT, FOXP3, GVHD, iTregs, Vit C
82  2018 A Lateral Neck Myeloid Sarcoma Presenting as Acute Otitis Externa. allo-SCT, AML, iEMR, MS
83  2018 Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation. aHSCT, GVHD, GVT, mHag
84  2018 Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. allo-HSCT, GVHD, IFN-gammaR, IL-6R
85  2018 Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes. GVHD, HSCT
86  2018 Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. CDLM, GVHD, HCT
87  2018 Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. DRPs, GVHD, mHAs, MUD, SCT
88  2018 Cord Haploidentical Non-In Vitro T Cell Depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse of Refractory Acute Leukemia. GVG, GVHD, HR, HSCT, PFS
89  2018 Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia. ALL, AML, HCT
90  2018 Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients. HSCT, KIRs, MRD, NK
91  2018 Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. aGvHD, aKIR, allo-HSCT, cGVHD, DFS, GVHD, HR, iKIR, KIR, NK cell, OR, OS, RR
92  2018 During acute graft versus host disease CD28 deletion in donor CD8+ , but not CD4+ , Tcells maintain antileukemia responses in mice. ---
93  2018 Flt-3L Expansion of Recipient CD8alpha+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD. BMT, DC, Flt3L, GVHD, PTCy
94  2018 Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes. BM, Flt3L, G-CSF, GVHD, pDCs, TCD
95  2018 Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells. DLI, GMP, GVHD, MHC
96  2018 Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. allo-HCT, GM-CSF, GVHD
97  2018 Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. GVHD, haplo-BMT, MAC, PT-BEN, PTCy
98  2018 Hematopoietic stem cell transplantation for acute myeloid leukemia. allo-HSCT, AML, auto, MSD, TRM
99  2018 Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease. ALL, allo-HSCT, MRD
100  2018 IL-10 gene-modified dendritic cells-induced type 1 T regulatory cellsinhibit graft-versus-host disease while preserving graft-versus-leukemia effect. allo-BMT, DCs, GVHD, IL, Th, Tr1